Document is current

Article History

Received: 27 November 2022

Accepted: 7 March 2023

First Online: 6 April 2023

Declarations

:

: N. Pfisterer received travel support from Abbvie and MSD. Mattias Mandorfer has served as a speaker and/or consultant and/or advisory board member for AbbVie, Bristol‐Myers Squibb, Gilead, Janssen and W. L. Gore & Associates and has received a research award from Medis. Thomas Reiberger received travel support from Boehringer‐Ingelheim, WL Gore, Gilead, Roche and MSD; grant support from Abbvie, Boehringer‐Ingelheim, Gilead, WL Gore, Phenex Pharmaceuticals and Philipps; served on advisory boards for Abbvie, Bayer, Boehringer‐Ingelheim, Gilead and MSD; and received lecture fees from Boehringer‐Ingelheim, Gore, MSD and Roche. Michael Trauner received travel support from Abbvie, Falk, Gilead, and Intercept and Jannsen; research grants from Albireo, Alnylam, Cymabay, Falk, Gilead, Intercept, MSD and Takeda and Ultagenyx; advisory board fees from Abbvie, Albireo, BiomX, Boehringer Ingelheim, Falk, Genfit, Gilead, Hightide, Intercept, Janssen, MSD, Novartis, Phenex, Pliant, Regulus, Siemens and Shire; lecture fees from BMS, Falk, Gilead, Intercept, and MSD and Roche; he is co-inventor of patents on the medical use of norUDCA filed by the Medical University of Graz. The other authors declared that they have no conflict of interest.

: This retrospective study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of the Medical University of Vienna (EK#1666/2015) and the ethics committee of the Wiener Gesundheitsverbund in Vienna (MA-15, EK#15-280-VK).